Allergic Rhinitis Drugs Market Size, Shares, Growth, Segments, Industry Analysis & Outlook 2018-2024

Our latest research report entitled Allergic Rhinitis Drugs Market (by class of drugs (immunotherapies, intranasal corticosteroids and antihistamines), route of administration (intranasal, oral and parenteral)) provides complete and deep insights into the market dynamics and growth of Allergic Rhinitis Drugs. Latest information on market risks, industry chain structure Allergic Rhinitis Drugs cost structure and opportunities are offered in this report. The past, present and forecast market information will lead to investment feasibility by studying the essential Allergic Rhinitis Drugs growth factors.

The forecast Allergic Rhinitis Drugs Market information is based on the present market situation, growth opportunities, development factors, and opinion of the industry experts. An in-depth analysis of the company profiles, Allergic Rhinitis Drugs on global and regional level and applications is conducted. The analysis of downstream buyers, sales channel, raw materials, and industry verticals is offered in this report. According to report the global allergic rhinitis drugs market is projected to grow at a CAGR of 3.8% over the forecast period of 2018-2024.

Ask for Sample Copy of Research Report with Table of Content @ https://www.infiniumglobalresearch.com/reports/sample-request/1298

Allergic rhinitis, or hay fever, is an allergic reaction to specific allergens. An allergen is an innocuous substance that causes an allergic reaction. This condition is usually caused by dust, animal dander, pollen, and certain food ingredients. Allergic rhinitis and sinusitis are related to each other, as allergic rhinitis blocks the nose, which in turn blocks the sinuses.

The market is expected to grow due to variety of drugs and nasal sprays are developed by manufacturers for the treatment of allergic rhinitis in the coming years. According to the American Academy of Allergy, Asthma, and Immunology (AAAAI) estimates at least 50 million people in the US are affected by nasal allergies from which 30% of adults and 40% of children, in 2015. Increase in the occurrence of allergic rhinitis is likely to boost the growth of this market growth. Furthermore, Rise in the awareness about allergic rhinitis and high usage of tobacco are some of the factor driving the growth of the market.

Among the regions, North America is expected to be the largest market for allergic rhinitis. High incidences of allergic rhinitis in regions like the US, Canada, and other part of North America. In 2017, Catalent Pharma Solutions Limited received approval for Odactra drug, from the U.S. Food and Drug Administration (FDA), the first allergen extract to be administered under the tongue (sublingually), to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), for people aged between18 and 65 years. Pediapharm Inc. launched an advanced allergy medication – Rupall, in a tablet and oral form, in 2017, which is a first prescription antihistamine with three indications namely, symptoms associated with seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic spontaneous urticaria (CSU), for children and adults aged 2 years and above suffering from the allergy.

Segment Covered

The report on global allergic rhinitis drugs market covers segments such as, class of drugs and route of administration. On the basis of class of drugs the global allergic rhinitis drugs market is categorized into immunotherapies, intranasal corticosteroids and antihistamines. On the basis of route of administration the global allergic rhinitis drugs market is categorized into intranasal, oral and parenteral.

Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-allergic-rhinitis-drugs